Target intelligence / Profile preview

Serotonin transporter (SLC6A4) (SERT)

Target
SERT
Molecular classification
Transporter, Solute carrier family, Neurotransmitter transporter, Sodium-coupled symporter
01

Overview

The serotonin transporter (SERT), encoded by the SLC6A4 gene, is an integral membrane protein responsible for the high-affinity reuptake of serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron (UniProt P31645). This transport process is driven by the electrochemical gradient of sodium and chloride ions and is the primary mechanism for terminating serotonergic signaling in the central nervous system (NIH/NCBI Gene). The central S1 substrate site is the primary binding pocket located in the core of the transporter's transmembrane bundle, where both the endogenous substrate and most clinical antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), bind (Coleman et al., Nature 2016). By occupying the S1 site, drugs prevent the transport of serotonin, leading to increased neurotransmitter availability and enhanced post-synaptic signaling, which is a cornerstone in the treatment of depression and anxiety (StatPearls). Beyond the brain, SERT is also expressed in blood platelets and the gastrointestinal tract, where it regulates peripheral serotonin levels and contributes to the drug's side effect profile, such as gastrointestinal upset and bleeding risks (PubMed).

Other names
5-HTT5-hydroxytryptamine transporterSodium-dependent serotonin transporterSolute carrier family 6 member 4HTTOCD1
02

Mechanism of action

Competitive inhibition of serotonin reuptake by binding to the central S1 substrate site, thereby increasing the concentration and duration of serotonin in the synaptic cleft.

03

Biological functions

Serotonin reuptakeNeurotransmission regulationSodium-dependent transportHomeostasis of extracellular serotoninPlatelet serotonin uptake
04

Disease associations

Major depressive disorderGeneralized anxiety disorderObsessive-compulsive disorderPost-traumatic stress disorderPanic disorderIrritable bowel syndromeAutism spectrum disorder
05

Safety considerations

Serotonin syndromeSexual dysfunctionGastrointestinal distressIncreased risk of suicidal ideation in children and young adultsAntidepressant discontinuation syndromeIncreased bleeding risk
06

Interacting drugs

Fluoxetine

13 more in the full profile.

07

Biomarkers

SLC6A4 gene polymorphisms (e.g., 5-HTTLPR)Platelet serotonin levelsPET imaging using [11C]DASB or [123I]ADAMWhole blood serotonin concentration

Beyond the preview

Go deeper on Serotonin transporter (SLC6A4) (SERT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin transporter (SLC6A4) (SERT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call